|Min SIP Amount||₹500|
|NAV||₹18.22 (18 Jun 2021)|
|Fund Started||28 Dec 2015|
|Fund Size||₹534 Cr|
|Dr. Reddy's Laboratories Ltd.||Healthcare||Equity||11.0%|
|Sun Pharmaceutical Inds. Ltd.||Healthcare||Equity||9.9%|
|Aurobindo Pharma Ltd.||Healthcare||Equity||9.2%|
|Divi's Laboratories Ltd.||Healthcare||Equity||8.2%|
|Alkem Laboratories Ltd.||Healthcare||Equity||5.8%|
|Ipca Laboratories Ltd.||Healthcare||Equity||4.9%|
|Apollo Hospitals Enterprise Ltd.||Healthcare||Equity||4.2%|
|Fortis Healthcare Ltd.||Healthcare||Equity||3.4%|
|Syngene International Ltd.||Healthcare||Equity||2.9%|
Tata India Pharma & HealthCare Fund Direct IDCW is a Equity Mutual Fund Scheme launched by Tata Mutual Fund. This scheme was made available to investors on 28 Dec 2015. Rupesh Patel, Sonam Udasi is the Current Fund Manager of Tata India Pharma & HealthCare Fund Direct IDCW fund.The fund currently has an Asset Under Management(AUM) of ₹534 Cr and the Latest NAV as of 18 Jun 2021 is ₹18.22.
The Tata India Pharma & HealthCare Fund Direct IDCW is rated Very High risk. Minimum SIP Investment is set to 500. Minimum Lumpsum Investment is 5000. Exit load of 0.25% if redeemed within 30 days.
The scheme seeks long term capital appreciation by investing atleast 80% of it's net assets in equity/equity related instruments of the companies in the pharma & healthcare sectors in India.
Returns are taxed at 15%, if you redeem before one year. After 1 year, you are required to pay LTCG tax of 10% on returns of Rs 1 lakh+ in a financial year.